Streamlining Rheumatology Prior Authorizations with Cognizant TriZetto Integration

For rheumatology practices leveraging Cognizant TriZetto for claims and prior authorization submissions, optimizing the PA workflow for high-cost biologics is critical for revenue cycle efficiency.

Rheumatology presents unique prior authorization challenges due to the chronic nature of conditions like RA and PsA, the high cost of biologic and targeted therapies, and intricate step therapy requirements. Navigating these complexities while utilizing a robust clearinghouse and payer platform like Cognizant TriZetto demands a strategic approach to automation and data exchange.

The Intersection of Rheumatology PA Demands and Cognizant TriZetto Capabilities

Rheumatology prior authorizations are characterized by a high volume of requests for biologics, JAK inhibitors, and infusion therapies, often requiring detailed clinical documentation per ACR guidelines. Cognizant TriZetto, as a leading clearinghouse and payer platform, facilitates the electronic submission and processing of these critical authorizations, acting as a key conduit between providers and health plans.

High-Volume Prior Authorization Triggers in Rheumatology

Biologic therapies: TNF-alpha inhibitors (e.g., Humira, Enbrel), non-TNF biologics (e.g., Stelara, Skyrizi), and JAK inhibitors (e.g., Rinvoq).
Specialty drugs for specific autoimmune indications, such as anifrolumab for SLE.
Advanced imaging for inflammatory arthritis assessment, including MRI.
DEXA scans for osteoporosis management in patients on chronic steroid therapy.
Infusion therapy administration for biologics like infliximab or rituximab.

Navigating Complex Documentation via Electronic Channels

Successful rheumatology prior authorizations hinge on precise documentation of ICD-10 codes, disease activity scores (DAS28, CDAI, PASI), and adherence to step therapy protocols. When submitting through platforms like Cognizant TriZetto, ensuring that all required clinical data is accurately captured and transmitted via electronic prior authorization (ePA) or X12 278 transactions is paramount to avoid denials and delays.

Key Documentation Requirements for Rheumatology Biologics

Diagnosis documentation aligned with criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA).
Disease activity assessment scores (e.g., DAS28, CDAI, PASI) to justify therapy.
Documentation of prior conventional DMARD trials (e.g., methotrexate) and their efficacy or contraindications.
Evidence of step therapy compliance, including biosimilar substitution where mandated by payer policy.
Completion of pre-screening for TB, hepatitis B/C, and immunization status for immunosuppressive agents.

Klivira's Role in Optimizing Rheumatology PA Workflows with TriZetto

Klivira integrates with EMRs to automate the collection of clinical data and applies ACR-guideline-aware logic to build complete prior authorization requests for rheumatology biologics. By streamlining the preparation process, Klivira ensures that requests are "clean" and ready for efficient submission through channels like Cognizant TriZetto, reducing manual effort and common denial reasons.

Addressing Chronic Treatment and Re-authorization Challenges

The chronic nature of rheumatologic conditions necessitates periodic re-authorization for ongoing biologic therapies, often every 6-12 months. Klivira's platform supports these continuous workflows, tracking re-authorization dates and prompting for updated disease activity and response documentation, ensuring seamless continuity of care when interacting with payer systems facilitated by Cognizant TriZetto.

Frequently asked questions

How does Klivira handle the variability in biosimilar substitution policies for rheumatology biologics when submitting through Cognizant TriZetto?

Klivira's platform incorporates payer-specific policy logic that distinguishes per-payer biosimilar mandates. This ensures that the prior authorization request, whether for a brand biologic or a biosimilar, aligns with the specific step therapy requirements before being submitted electronically, potentially via a clearinghouse like Cognizant TriZetto.

What common rheumatology PA denial reasons can Klivira help mitigate when using a clearinghouse like TriZetto?

Klivira addresses common denial reasons such as incomplete step therapy documentation, missing disease activity scores (e.g., DAS28, PASI), and insufficient screening records. By automating data extraction and applying rule-based logic, Klivira helps ensure all necessary information is present and accurate before submission, reducing back-and-forth with payers.

Can Klivira assist with the medical vs. pharmacy benefit split for rheumatology biologics administered via infusion or self-injection?

Yes, Klivira's system is designed to route prior authorization requests appropriately based on whether the biologic is covered under the medical or pharmacy benefit. This is crucial for rheumatology, where the same drug may fall under different benefits depending on the administration mode, ensuring correct submission to the relevant payer channel.

How does Klivira support the ongoing re-authorization process for chronic rheumatology treatments?

Klivira provides a periodic re-authorization workflow for chronic-treatment biologics. The platform tracks re-authorization due dates and facilitates the continuous documentation of disease response, ensuring that updated clinical information is prepared and submitted to payers, maintaining continuity of approved therapies.

What role do clinical guidelines like ACR play in Klivira's automation for rheumatology PAs?

Klivira's policy logic is built to be ACR-guideline-aware, particularly for step therapy sequencing per indication (e.g., RA, PsA, AS, SLE). This ensures that the automated PA requests align with recognized clinical pathways and payer expectations, strengthening the case for approval.